Company Profile For Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical and nutritional products. The Company had two segments: Pharmaceuticals and Nutritionals. The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula and children’s nutritionals business. In June 2008, BMS acquired Kosan Biosciences, Inc., a developer of oncology products. In August 2008, the Company completed the divestiture of its ConvaTec business to Cidron Healthcare Limited, an affiliate of Nordic Capital Fund VII and Avista. In December 2008, BMS completed the sale of its brand business in Egypt to GlaxoSmithKline. In July 2009, the Company's branded generics business, which comprises a portfolio of 13 branded pharmaceuticals was acquired by GlaxoSmithKline plc.

BRIEF: For the nine months ended 30 September 2009, Bristol Myers Squibb Co.'s revenues increased 4% to $15.89B. Net income from cont. ops. increased 32% to $2.57B. Revenues reflect an increase in income from biopharmaceuticals. Net income also reflects a decrease in the cost of products sold, lower marketing, selling & administrative expenses, a fall in the advertising & product promotion costs and an increase in operating margins.